Marshall Wace, LLP Hutchmed (China) LTD Transaction History

Marshall Wace, LLP

$90.8 Billion
Q3 2025

A detailed history of Marshall Wace, LLP transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Marshall Wace, LLP holds 14,897 shares of HCM stock, worth $224,646. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,897

Previous 19,882 25.07%

Holding current value

$224,646

Previous $299,000 21.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$14.83 - $19.21 $73,927 - $95,761	-4,985 Reduced 25.07%	14,897 $234,000
Q2 2025 Aug 13, 2025	BUY	$11.81 - $17.72 $2,999 - $4,500	254 Added 1.29%	19,882 $299,000
Q1 2025 May 15, 2025	BUY	$13.09 - $16.75 $19,975 - $25,560	1,526 Added 8.43%	19,628 $295,000
Q4 2024 Feb 13, 2025	BUY	$14.25 - $21.35 $257,953 - $386,477	18,102 New	18,102 $260,000
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $24,375 - $30,345	1,500 Added 9.74%	16,900 $306,000

Q3 2023 Nov 14, 2023	SELL	$11.85 - $16.95 $303,004 - $433,411	-25,570 Reduced 62.41%	15,400 $260,000
Q2 2023 Aug 14, 2023	BUY	$10.78 - $17.73 $182,257 - $299,761	16,907 Added 70.26%	40,970 $491,000
Q1 2023 May 15, 2023	BUY	$13.02 - $19.87 $313,300 - $478,131	24,063 New	24,063 $313,000
Q2 2021 Aug 13, 2021	SELL	$23.7 - $39.27 $912,639 - $1.51 Million	-38,508 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$27.01 - $36.8 $1.04 Million - $1.42 Million	38,508 New	38,508 $1.09 Million
Q4 2019 Feb 14, 2020	SELL	$17.17 - $25.95 $176,181 - $266,272	-10,261 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$17.84 - $22.69 $183,056 - $232,822	10,261 New	10,261 $183,000

Others Institutions Holding HCM

# of Institutions

Shares Held

5.74M

Call Options Held

Put Options Held

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.61B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Hutchmed (China) LTD Transaction History